Search Results - "Mottola, Leonardo"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    What's new in HCV genotype 2 treatment by Mangia, Alessandra, Mottola, Leonardo

    Published in Liver international (01-02-2012)
    “…Genotype 2 (HCV‐2) accounts for 8% of the patients with chronic hepatitis C virus in Europe. Because of the favourable response to interferon (IFN)‐based…”
    Get full text
    Journal Article
  5. 5

    Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients by Mangia, Alessandra, Mottola, Leonardo, Santoro, Rosanna

    Published in World journal of gastroenterology : WJG (21-12-2013)
    “…Single nucleotide polymorphisms near the interleukin 28B (IL-28B) gene have been identified as strong predictors of both spontaneous or Peg-interferon…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Treatment of Non-Genotype 1 Hepatitis C Virus Patients by Mangia, Alessandra, Mottola, Leonardo

    Published in Current gastroenterology reports (01-02-2012)
    “…The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in…”
    Get full text
    Journal Article
  8. 8

    Limited use of interleukin 28B in the setting of response‐guided treatment with detailed on‐treatment virological monitoring by Mangia, Alessandra, Thompson, Alexander J., Santoro, Rosanna, Piazzolla, Valeria, Copetti, Massimiliano, Minerva, Nicola, Petruzzellis, Daniela, Mottola, Leonardo, Bacca, Donato, McHutchison, John G.

    Published in Hepatology (Baltimore, Md.) (02-09-2011)
    “…A single‐nucleotide polymorphism upstream of the interleukin‐28B (IL28B) gene is associated with pegylated interferon‐alfa–induced viral clearance in hepatitis…”
    Get full text
    Journal Article
  9. 9

    Update on the Treatment of Patients With Non—Genotype 1 Hepatitis C Virus Infection by Mangia, Alessandra, Mottola, Leonardo, Piazzolla, Valeria

    Published in Clinical infectious diseases (01-05-2013)
    “…Current treatment for patients with non—genotype 1 hepatitis C virus infection consists of pegylated interferon plus ribavirin for 24 weeks, which leads to…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    RIBAVIRN DOSAGE IN HCV GENOTYPES 2 AND 3 PATIENTS COMPLETING SHORT THERAPY WITH PEG-INTERFERON ALFA-2B AND RIBAVIRIN by Mangia, Alessandra, Dalgard, Olav, Minerva, Nicola, Bacca, Donato, Ring-Larsen, Helmer, Copetti, Massimiliano, Carretta, Vito, Piazzolla, Valeria, Cozzolongo, Raffaele, Mottola, Leonardo

    Published in Alimentary pharmacology & therapeutics (08-03-2010)
    “…Background. Optimal dose of ribavirin to be used in combination with Peg-IFN in HCV genotype 2/3 patients undergoing short treatment has not been established…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Principles, techniques, and limitations of near infrared spectroscopy by Ferrari, Marco, Mottola, Leonardo, Quaresima, Valentina

    Published in Canadian journal of applied physiology (01-08-2004)
    “…In the last decade the study of the human brain and muscle energetics underwent a radical change, thanks to the progressive introduction of noninvasive…”
    Get more information
    Journal Article
  19. 19